<DOC>
	<DOC>NCT01453244</DOC>
	<brief_summary>The aim of this study is to investigate the relationships between drug response and the host genetic factors, viral factors and clinical factors in chronic hepatitis C patients (HCV). And thus, the investigators are trying to develop the pharmacogenomic guideline in the Korean patients with HCV.</brief_summary>
	<brief_title>Pharmacogenomic Research in Korean Patients With Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Hepatitis C virus infected patients Patients who infected Hepatitis B virus or Human immunodeficiency virus HCV infected patients previously treated with antiviral drugs Patients had a history of autoimmune hemolytic anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Pharmacogenomics</keyword>
	<keyword>IL28B</keyword>
	<keyword>ITPA</keyword>
</DOC>